Will the UK's National Institute for Health and Care Excellence (NICE) issue updated guidance recommending Teplizumab for a broader patient group (e.g., younger children) by December 31, 2026?
Resolves: YES if NICE publishes updated guidance explicitly recommending Teplizumab for a patient group not covered by its initial recommendation (e.g., a significantly younger age bracket) by the specified date. NO otherwise.
Will the UK's National Institute for Health and Care Excellence (NICE…
Market overview
Initial availability often targets specific patient cohorts. This question explores whether the drug's proven efficacy and safety will lead to expanded recommendations for its use within the NHS framework.
Legal prediction market
- Implied probability (Yes)
- 45%
- Closes
- 2026-12-31
About this prediction
How this resolves
YES if NICE publishes updated guidance explicitly recommending Teplizumab for a patient group not covered by its initial recommendation (e.g., a significantly younger age bracket) by the specified date. NO otherwise.
Source: user-generated
More Legal markets
- Will Baviskar's trading accounts be permanently restricted by November 25, 2026? — 95% Yes
- Will Ichcoin Tech Corp. settle with the SEC within 90 days? — 75% Yes
- Will any individual respondent settle with the SEC before year-end 2026? — 30% Yes
- Will the SEC announce a freeze on Ferder's personal assets by November 30, 2026? — 70% Yes
- Will Bonanza Global investors recover more than $1M by November 2026? — 25% Yes
- Will at least one respondent comply with subpoenas within 30 days of court order? — 65% Yes
- Will the court impose a civil penalty on Chavez by 2026-12-01? — 90% Yes
- SEC drops enforcement actions against major crypto exchanges within 12 months — 55% Yes